INTRODUCTION
In the perinatal setting, chromosome abnormalities span a wide range of genomic imbalance, from polyploidy (the presence of 3 [triploidy] or 4 [tetraploidy] copies of every chromosome), to whole-chromosome aneuploidy (typically involving only a single chromosome), to submicroscopic deletions and duplications that can only be detected by DNA-based copy number methods, such as fluorescence in situ hybridization (FISH) or chromosomal microarray (CMA). As technologies have improved to detect smaller and smaller copy number variants (CNVs) across the genome, clinicians are learning the high frequency and important role that this type of genomic variation plays in human health and development.
CNVs have been identified as a common cause of several human diseases, many of which present in the neonatal period and/or early childhood. These diseases include neurodevelopmental disorders (such as autism, intellectual disability, and epilepsy), congenital heart defects, and other congenital anomalies. [1] [2] [3] However, not all CNVs are disease causing: some CNVs have been identified in apparently normal individuals. 4, 5 Whether a CNV is disease causing or not depends on many factors, such as gene content (eg, a CNV that is gene rich is more likely to cause a phenotype than one containing few or no genes). 6 Therefore, understanding the corresponding phenotypic effects of particular CNVs is becoming increasingly important in clinical medicine so clinicians can define which CNVs cause a clinical phenotype versus those that are part of normal variation.
This article highlights key aspects of copy number detection during the prenatal and neonatal periods. Many infants presenting to neonatology services for a possible genetic diagnosis may have had prenatal testing; it is important to understand which test was performed to interpret the results and know whether additional genetic testing is warranted. In contrast, if prenatal testing was not done, then decisions need to be made about which genetic tests are most appropriate to order. To make informed test ordering decisions, it is important for neonatologists and other providers to understand the limitations and benefits of the various laboratory technologies. Therefore, this article compares methods for CNV detection. It also explores some of the most common CNVs associated with disease and how interpretation of CNVs is accomplished through the use of various resources, including online genomic databases. Given that CNVs are now appreciated as one of the most frequent causes of a broad spectrum of human disorders, early diagnosis and accurate interpretation is important to implement timely interventions and targeted clinical management.
METHODS FOR THE DETECTION OF COPY NUMBER VARIANTS
Various methods have been developed over the years for the detection of chromosomal deletions, duplications, and rearrangements. As shown in Fig. 1 , some of these methods allow genomewide analyses, in which the entire chromosome complement is being interrogated, whereas others are targeted analyses and only examine specific regions of the genome. In addition, methods differ in their level of resolution (ie, how small an imbalance can be detected) and the type of sample that can be analyzed. Table 1 summarizes the most commonly used cytogenetic methods for the detection of chromosome abnormalities and compares the benefits and limitations of each.
Of the techniques listed in Table 1 , Giemsa-banded (G-banded) chromosome analysis and CMA are the only ones that are considered genomewide analyses, in which the entirety of each chromosome is being analyzed. However, the resolution of CMA far exceeds that of G-banding; genomic imbalances that could only be approximated by G-banding analysis can now be measured with precision by CMA based on the ability to link the probes contained on a microarray with the underlying DNA sequence coordinates. For these reasons, and others detailed later, CMA has become the firsttier test for clinical cytogenetic testing in the pediatric setting.
Most genomewide microarrays used for clinical CMA now also include singlenucleotide polymorphism (SNP) probes in addition to probes used for copy number detection. The addition of SNP probes offers several advantages. For example, SNP probes allow the detection of triploidy and some cases of tetraploidy. 7 These abnormalities are usually not detectable by copy number analyses alone, but are important to identify in the prenatal setting because both are common causes of fetal loss. In addition, genomic regions with an absence of heterozygosity (AOH) may be detected. AOH can suggest the presence of uniparental disomy (UPD), in which homologous chromosomes are both inherited from the same parent, instead of 1 from each parent. UPD for certain chromosomes has been associated with genetic disorders, such as Prader-Willi syndrome, when both chromosomes 15 are inherited from the mother in about 20% to 25% of cases. AOH can also distinguish genomic regions that are identical by descent, which could increase risk for an autosomal recessive disorder if a deleterious mutation is present. The use of SNP arrays for these indications is not a diagnostic test; however, both of these findings could prompt The thick black lines correspond with the lower resolution obtained from traditional G-banding analysis, whereas the thin black lines correspond with the higher resolution from newer techniques, like CMA. This example shows that CMA can detect an imbalance of 1 Mb that would be missed by G-banding. G-banding could only detect larger imbalances, such as the 10 Mb abnormality shown. (B) Targeted analysis. The only chromosomes being analyzed by targeted analysis are shown in black. The gray chromosomes would not be analyzed by targeted tests. targeted diagnostic testing for UPD or sequencing of a specific autosomal recessive gene based on the patient's clinical phenotype. 8 In contrast with genomewide methods, targeted methods for the detection of cytogenetic aberrations are used to examine specific regions of the genome, such as aneuploidy for a single chromosome or deletion/duplication of a region associated with a known genetic syndrome. With the adoption of CMA, most targeted tests for microdeletion or microduplication syndromes are not used anymore, because many of these syndromes lack distinctive phenotypic findings and CMA can test for multiple regions in 1 assay instead of testing for 1 disorder at a time. 1 Targeted tests are still predominantly used for aneuploidy testing of the chromosomes most frequently involved in human disorders, including 13, 18, 21, X, and Y, particularly in the prenatal setting or when a trisomy is suspected in a neonate based on clinical features. Table 1 compares 2 targeted methods for aneuploidy detection: FISH and noninvasive prenatal screening (NIPS; discussed later in more detail).
PRENATAL DIAGNOSIS OF COPY NUMBER VARIANTS
As mentioned earlier, infants presenting to neonatology services for a possible genetic diagnosis may or may not have had prenatal testing. It is important for providers to understand these laboratory tests and their results to accurately determine whether any additional genetic testing is necessary. For example, if the mother had an amniocentesis with chromosome analysis during pregnancy and that test was normal, has a chromosome abnormality been ruled out or should other genetic testing be pursued?
Amniocentesis was first shown to be a safe and accurate method for prenatal diagnosis of genetic anomalies in the early 1970s. 9 Since that time, approaches to prenatal screening and diagnosis for chromosomal aberrations have quickly evolved based on new technologies and emerging practices. When considering results from prenatal testing, it is important to understand the difference between diagnostic and screening tests, and between genomewide versus targeted testing, because different levels of information are obtained.
Diagnostic tests provide an accurate representation of the fetal chromosome complement; currently, all prenatal diagnostic tests require an invasive procedure, such as amniocentesis or chorionic villi sampling, to obtain a sample directly from the fetus or placenta. In contrast, screening tests have risks for false-positive and false-negative results, because the sample is not being directly obtained from the fetus. Some commonly used noninvasive screening tests for aneuploidy, which are performed on a blood sample from the mother of the fetus, include maternal serum screening and NIPS.
G-banded chromosome analysis has historically been the gold-standard for detecting genomewide prenatal chromosome abnormalities. However, several large studies have now compared the diagnostic yield of G-banding with genomewide CMA for prenatal diagnosis and have shown that a significant proportion of clinically relevant chromosome aberrations are missed by G-banding alone. 10, 11 Callaway and colleagues 11 (2013) recently performed a systematic review of the literature, including more than 12,000 prenatal cases that had CMA after a normal karyotype. This analysis revealed clinically significant CNVs in 2.4% of cases, with the highest yield in cases ascertained for abnormal ultrasonography (6.5%). However, even cases referred because of increased maternal age or for other reasons, such as abnormal serum screening or parental anxiety, had significant yields of 1.0% and 1.1%, respectively. Despite these data, in the prenatal setting, array is still not considered standard of care for all pregnancies. The most recent recommendations from the American Congress of
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Obstetricians and Gynecologists (ACOG), published in 2013, allow CMA to replace a G-banded karyotype when ultrasonography anomalies are detected and invasive testing is being pursued. Either a karyotype or CMA can be used in patients undergoing invasive testing with a structurally normal fetus. 12 Therefore, if only a G-banded karyotype is performed prenatally and is normal, CMA should be ordered in a neonate presenting with features suggestive of a chromosomal disorder. Box 1 lists some of the most common clinical features that should prompt consideration of a chromosomal disorder; the presence of more than 1 of these findings in a patient raises the suspicion for a genetic cause proportionately.
A rapidly evolving field in prenatal diagnosis is NIPS, also referred to as noninvasive prenatal testing. Even though a recent study showed no increased risk for fetal loss caused by invasive procedures, 13 the misperception that any invasive test carries some increased risk for fetal loss still exists. In addition, some women do not want invasive testing, independent of the risk for fetal loss. These two issues have been the main driving factors for technological developments for noninvasive screening methods and the uptake of noninvasive testing by patients. With the advent of NIPS in 2011, the number of amniocentesis and chorionic villi sampling procedures has significantly decreased, as shown by data from several maternal-fetal medicine centers. [14] [15] [16] [17] NIPS is based on the detection of cell-free fetal DNA in maternal plasma using next-generation sequencing or other methods for fetal DNA assessment. 14, 18 At this time, NIPS is mainly used for the targeted detection of common aneuploidies (13, 18, 21, X, and Y; shown in Fig. 1B) . However, the technology is already being refined to detect common microdeletion/duplication syndromes as well as genomewide CNVs. 19 Because NIPS is currently only a targeted screening test, a complete evaluation of the fetal genome is not obtained and clinically significant chromosome abnormalities could be missed. In addition, several cases of discordant results between NIPS and diagnostic cytogenetic testing have been reported. 20, 21 Therefore, in the context of a neonate presenting with features suggestive of a chromosomal disorder, if the only result from prenatal genetic testing is a normal NIPS test, additional genetic testing is warranted.
COPY NUMBER DETECTION IN THE NEONATAL PERIOD
Although some chromosome abnormalities may be suspected and tested for in the prenatal period because of ultrasonography abnormalities or other clinical indications, most are not suspected until birth when dysmorphic features, congenital malformations, or other anomalies are observed. Early studies of the frequency of chromosome abnormalities in newborns estimated the rate to be w4% from chromosome analysis. 22, 23 Aneuploidies of chromosomes 21, X, and Y were the most common abnormalities detected, with trisomy of chromosomes 13 or 18, unbalanced rearrangements, and supernumerary chromosomes occurring less frequently.
With the advent of CMA it was hypothesized that the contribution of chromosomal imbalances in neonates was being underestimated. This hypothesis was proved to be correct by a large study of 638 neonates with various birth defects who were referred for clinical CMA. 24 Clinically significant imbalances were detected in 17.1% of patients, most of which would not have been identified by G-banding analysis. Although there were various reasons for referral for CMA testing among the samples with abnormal findings, the highest diagnostic yield was observed in the authordefined category "possible chromosome abnormality AE other birth defect" (66.7%). Other high-yield clinical indications were "ambiguous genitalia AE other birth defect" (33.3%), "dysmorphic features with multiple congenital anomalies AE other birth defect" (24.6%), and "congenital heart disease AE other birth defect" (21.8%). Overall, 2.5% of abnormal cases had whole-chromosome aneuploidies, whereas 12.7% had deletions or duplications.
Importantly, at the time of this study, high-resolution genomewide CMA analysis had not yet been developed for clinical testing. The arrays used in this study were targeted arrays (containing coverage over known clinically relevant regions of the genome, such as microdeletion/duplication syndromes, telomeres, and centromeres) with only low-resolution coverage across the rest of the genome, corresponding with approximately 1 targeted region per chromosome band at the 650-band level of resolution (w5-10 Mb). Even with coverage at a lower resolution than used in currently available clinical arrays, this study still identified abnormalities in a significant number (17.1%) of neonates. With the higher resolution arrays currently being used, this diagnostic yield is predicted to be even greater, showing the importance of CMA in the clinical care of neonates.
Because congenital heart defects (CHDs) are among the most common birth defects, and also a common indication for cytogenetic testing in the neonatal period, many studies have focused on the contribution of CNVs to isolated CHDs and CHDs with other associated defects. A recent review including data from 20 studies examined the diagnostic yield of CMA in CHDs. 3 Clinically relevant CNVs were reported in 3% to 25% of patients with CHDs plus other associated defects, with many of these studies in the 17% to 20% range. Even in cases with isolated CHDs, the diagnostic yield was still significant, with 3% to 10% of cases having a clinically relevant CNV. Thus most CHDs, whether observed in the context of additional phenotypic findings or as isolated defects, warrant consideration of CMA to detect pathogenic CNVs.
The most common submicroscopic CNV associated with CHDs is a deletion of 22q11.2. This CNV is estimated to occur in 1 in 2000 to 1 in 4000 live births. In addition to CHDs, the most common being conotruncal defects, individuals with a 22q11.2 deletion can show various clinical features, including palatal abnormalities, hypocalcemia, immune deficiency, and a range of neurodevelopmental disorders. 25 In w10% of cases, this deletion is inherited from an affected parent who usually has a more mild presentation than the proband; therefore, parental testing to determine inheritance is important for recurrence risk estimates and familial genetic counseling.
More broadly, the implementation of high-resolution genomewide CMA for other common postnatal indications, such as developmental delay, intellectual disability, autism spectrum disorder, or multiple congenital anomalies, has also shown a diagnostic yield that far surpasses that of G-banding. A systematic literature review of 33 CMA studies of these patient populations estimated that w15% to 20% have a clinically relevant CNV, compared with a yield of only w3% from G-banding (the 3% estimate excluded Down syndrome and other recognizable chromosomal syndromes). 1 These data ultimately resulted in CMA being recommended as the firsttier clinical test for individuals with developmental disorders or congenital anomalies by several groups, including the American College of Medical Genetics and Genomics (ACMG). 1, 26 
CLINICAL INTERPRETATION OF COPY NUMBER VARIANTS
The use of CMA has obvious advantages compared with previous cytogenetic methods for diagnostic yield. Another invaluable benefit of CMA as a diagnostic test is the ability to immediately link the genomic coordinates from the DNA probes contained on the array to the human genome sequence to evaluate size, gene content, and other elements that make up the architecture of the human genome. With the wide range of copy number variation present in the human genome, clinicians are still learning which variation in individuals is causative of disease and which has a benign or negligible impact. Cataloging both benign and pathogenic regions of the genome is imperative to aid in the clinical interpretation of CNVs.
Recurrent and Nonrecurrent Copy Number Variants
The collection of CNVs from across the genome allows the comparison of overlapping CNVs to determine underlying mechanisms and the resulting phenotypic effects. Although it has been estimated that most (w75%) CNVs occur at nonrecurrent sites across the genome, w25% of CNVs are mediated by nonallelic homologous recombination between flanking sequences of shared DNA sequence homology (commonly referred to as segmental duplications or genomic hotspots) and make up a class of CNVs termed recurrent CNVs. 27, 28 Because these CNVs, which contain identical unique genomic regions of imbalance across patients, recur because of their underlying mechanism, they are frequently encountered during CMA analysis. Table 2 lists some of the most frequently observed recurrent CNVs that are encountered during clinical CMA testing. Some of these CNVs (eg, Prader-Willi/Angelman syndromes and 22q11.2 deletion syndrome) have been described for some time now because they were associated with a specific syndrome and detected either through high-resolution G-banding or FISH analyses. Other CNVs, with more variable phenotypes (eg, deletions and duplications of 1q21.1 and 16p11.2), have only emerged recently because of the ability to detect smaller imbalances across the genome via CMA. Targeted research studies comparing the phenotype of individuals with many of these recurrent CNVs are now underway to better define the deleterious impact of each CNV. 29, 30 
Interpretation Guidelines
The technical definition of a CNV is "a segment of DNA that is ! 1 kilobase (kb) in size that differs in copy number compared with a representative reference genome." 31 However, most CNVs that are less than w400 kb are observed frequently in cohorts of apparently normal control individuals, and are therefore not thought to have appreciable effects on human health and/or development. 32 Because of this, for the purposes of detecting CNVs as part of clinical testing, several organizations have recommended a resolution of greater than or equal to 400 kb across the genome to avoid detection of these common, benign CNVs. 1, 33 Some array designs used by clinical laboratories contain higher resolution coverage (w20-50 kb) over known diseasecausing genes in order to detect single gene deletions or duplications.
Note that the term CNV must be qualified with additional information in order to understand the clinical relevance of the finding: (1) a CNV must be designated as a deletion or duplication, and (2) a CNV should have a defined category of clinical significance.
As outlined in Table 3 , the ACMG has defined 5 categories for interpreting the clinical significance of CNVs and examples of each are listed. CNVs included on clinical reports should be classified into one of these categories so that clinicians can review the laboratory findings and correlate with their patient's clinical phenotype. It is common (w10% of cases) for a CNV to be reported as of uncertain clinical significance based on the limited information that the laboratory had at the time of testing, but when a clinician reviews the CNV detected and pairs it with more detailed phenotypic data from the patient, a more definitive interpretation of "pathogenic" can often be made. This example highlights the critical need for coordinated communication between clinical laboratories and clinicians for accurate interpretation of genomic testing.
When a CNV is identified, several characteristics of the genomic region that is either deleted or duplicated need to be considered in interpreting its significance. The following bulleted list documents some of the basic questions to investigate:
1. Is the CNV included in databases of normal variation? If so, the CNV is considered a benign variant. If not, then the potential pathogenicity needs to be evaluated. 2. Does the CNV contain a region of the genome known to cause a genomic syndrome when deleted or duplicated (eg, a recurrent CNV region associated with a particular phenotype)? If so, then the CNV would be consistent with causing the syndrome that corresponds with either a deletion or duplication of that region, depending on the CNV finding. 3. Does the CNV contain a gene that is known to cause a syndrome as a result of haploinsufficiency (deletion) or triplosensitivity (duplication)? If so, then the CNV that encompasses the entire gene would be consistent with causing the syndrome that corresponds with either a deletion or duplication of that gene, depending on the CNV finding. 4. If the CNV does not overlap a known region or gene, what is the gene content and size of the CNV? In general, a larger imbalance with high gene content is more likely to be considered pathogenic. 5. Is the CNV de novo? In general, a de novo CNV is more likely to be pathogenic than one inherited from a parent with an apparently normal phenotype. 6. Is the CNV inherited? If a CNV is inherited, then it is important to evaluate the phenotype of the parent carrying the same CNV. The parent could be affected with the same clinical phenotype as the proband. Alternatively, the parent could have more subtle phenotypic effects than the proband caused by variable expressivity of the CNV. The CNV could also be a benign variant if it is observed frequently in the general population.
Genomic Resources for Copy Number Variant Curation
Even though new genomic discoveries are made and published every day, the interplay between genomic variants and their impact on various systems involved in human development and function are still not known. Because many genomic variants are CNVs, Aneuploidies, and Disease 27, [38] [39] [40] [41] Abbreviation: BP, breakpoint. a Genes in the CNV region are included as landmarks for genomic location and are not necessarily known to be causative of phenotype. rare, community efforts are needed to assist in deciphering the clinical significance of genomic variants in an evidence-based manner. Toward the goal of curating genomewide CNVs, multiple online genome resources, as detailed by de Leeuw and colleagues 34 (2012), have been garnered from large-scale data sharing and are now publically available. Table 4 lists some of the online resources for CNVs and their corresponding phenotypes that are most commonly used for interpreting clinical significance. The table includes 3 different types of tools that can be used to aid in CNV interpretation: (1) genome browsers, in which the genomic coordinates of a particular CNV can be entered and the browser used to view its genomic content; (2) databases of CNVs submitted from case and control cohorts, which can be used to compare individual cases with other previously observed CNVs; (3) catalogs of phenotypic information collected from the literature or written by experts that provide overviews of well-described syndromes or gene/disease associations. All of these resources are dynamic and evolving at a rate that largely depends on the discovery, data submission, and curation efforts of researchers, clinical laboratories, clinicians, and others. 
SUMMARY
CNVs provide a genetic cause for a wide range of disorders diagnosed in the prenatal and neonatal periods. There are a growing number of examples in which knowing a genetic cause leads to genome-directed clinical care and improved medical management. For example, in neonates with 22q11.2 deletions, not only is it important to assess for all of the congenital anomalies associated with this CNV, it is also important to monitor neonatal calcium levels. A recent study showed that neonatal seizures and neonatal hypocalcemia were predictors of a more severe level of intellectual disability. The investigators thus concluded that early monitoring of calcium levels before seizure onset might improve outcomes in these patients by preventing damage to neurons caused by seizures. 35 The continuing evolution of genomic technologies for the detection of CNVs and aneuploidy in the perinatal setting will allow earlier diagnosis of these conditions in fetuses and neonates. Next-generation whole-exome sequencing (WES) and wholegenome sequencing (WGS) methods are already being used to detect CNVs in postnatal samples and the feasibility of using WGS for noninvasive sequencing of a human fetus by analyzing parental blood samples was recently reported. 36, 37 As the decreasing costs of WES and WGS make broader adoption possible, an era of genomic medicine can be envisioned in which it is feasible to routinely perform these genomewide methods for variant detection on neonatal, or ultimately prenatal, samples collected noninvasively. Through increasing understanding of the interplay between genomic variants and health, there is the potential to realize the full benefits of personalized genomic medicine, resulting in earlier interventions and improved outcomes.
